Extrait

The primary objective of the present study is to obtain safety reassurance with the use of Iron oligosaccharide given either as repeated IV boluses or as total dose infusion (TDI) for the correction of anaemia in patients with CHF in order to ensure that Iron oligosaccharide will not lead to unexpected adverse events in CHF patients.

Critère d'inclusion

• Patients with anaemia and who have a need for parenteral iron due to either absolute or functional iron deficiency anaemia will be included. Patients may receive concomitant Erythropoeisis Stimulating Agents treatment according to hospital standards but this is not a requirement for participation. Patients previous treated with parenteral iron therapy but still needing further Iron who fullfils the inclusion criteria may be switched from an existing parenteral iron treatment

Liens

• ictrp
• euctr